Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 240 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Surgery, Colon Clear all

Conditions: Anal Cancer, Colorectal Cancer, Perioperative/Postoperative Complications
Interventions: conventional surgery, management of therapy complications; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: folic acid; Dietary Supplement
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 21 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: Colorectal Carcinoma, Peritoneal Carcinomatosis
Interventions: Laparotomy+ HIPEC +/- CRS; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Neoplasms
Interventions: MEDI6469; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Colorectal Cancer, Comprehensive Transitional Care Program
Interventions: Patient education: One-on-one visit, Discharge planning: Assessment of barriers to discharge, Medication reconciliation: Patient medication review, Appointment before discharge: Additional measure to ensure awareness of next clinic visit, Transition coach, Patient-centered discharge instructions: Enhanced, Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology, Timely follow-up: Barriers to clinic follow-up visits will be discussed, Timely PCP communication, Follow-up telephone call, Patient hotline: 24 hour follow-up following call to Ask My Nurse number; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: bevacizumab, fluorouracil, leucovorin, oxaliplatin; Biological · Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 163
States / cities: Little Rock, Arkansas • Duarte, California • Fremont, California + 122 more

Conditions: Colorectal Lesion, Colorectal Adenoma, Colorectal Polyp, Rectal Lesion, Rectal Adenoma, Rectal Polyp, Sigmoid; Lesion, Sigmoid Colon Polyp
Interventions: Endoscopic submucosal dissection using the ELS System; Device
Lead sponsor: EndoQuest Robotics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Scottsdale, Arizona • Orlando, Florida • Boston, Massachusetts + 2 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation; Biological · Drug · Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Gastric Cancer, Colon Cancer
Interventions: Cook Medical EMR Gel; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Colonic Diseases, Rectal Diseases
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colorectal Cancer
Interventions: selenomethionine, capecitabine, oxaliplatin, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy; Dietary Supplement · Drug · Other + 2 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis, Pain, Postoperative, Ileus, Ileus Paralytic, Ileus; Mechanical, Constipation Drug Induced, Constipation, Rectum Cancer, Rectum Neoplasm
Interventions: Acetaminophen, Gabapentin, Orphenadrine, Lidocaine, Marcaine, Ketamine, Methadone, Tramadol, Ketorolac, Morphine Sulfate, Fentanyl, Dilaudid, Hydrocodone-Acetaminophen Tab 5-325 MG, HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET; Drug
Lead sponsor: University of Illinois College of Medicine at Peoria; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Colorectal Adenoma, Colorectal Carcinoma
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
Interventions: Bevacizumab, Fluorouracil, Leucovorin Calcium, Oxaliplatin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colon Cancer, Rectal Cancer, Colonic Diverticulosis
Interventions: TAP Block, Continuous Epidural Analgesia; Procedure
Lead sponsor: Trinity Health Michigan; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions: ActivSight; Device
Lead sponsor: Activ Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Buffalo, New York • Houston, Texas • Sugar Land, Texas

Conditions: Colon Cancer
Interventions: Gevokizumab, Signatera test; Drug · Diagnostic Test
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Gainesville, Florida • Iowa City, Iowa • New Brunswick, New Jersey + 2 more

Conditions: Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Zanidatamab, Resection, Patient Observation, Echocardiography Test, Multigated Acquisition Scan, Endoscopic Procedure, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy Procedure, Digital Rectal Examination, Electronic Health Record Review; Biological · Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Hepatectomy, Pembrolizumab, Vactosertib; Procedure · Biological · Drug
Lead sponsor: Chloe Atreya, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: gemcitabine hydrochloride, floxuridine, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, liquid chromatography, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study; Drug · Genetic · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Duarte, California

Conditions: Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration, Toripalimab; Procedure · Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Colorectal Cancer, Precancerous Condition
Interventions: rosuvastatin, placebo; Drug · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 584
States / cities: Anniston, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 423 more

Conditions: Colorectal Cancer
Interventions: cetuximab, capecitabine, oxaliplatin, therapeutic surgical procedure, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 130
States / cities: Mobile, Alabama • Tucson, Arizona • Berkeley, California + 93 more

Conditions: Colorectal Cancer, Tumor, CRC, GI Cancer, Gastrointestinal Cancer
Interventions: Not listed
Lead sponsor: Viome; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Bellevue, Washington

Search by objective public record fields.

Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer

High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery

PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections

Assessing Infectious Risk and Visceral Closure in Natural Orifice Translumenal Endoscopic Surgery (NOTES)

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Trial Comparing Transversus Abdominis Plane Block Versus Epidural Anesthesia for Pain Management in Colorectal Surgery

Safety and Feasibility of ActivSightTM in Human

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

Microbiome in Colorectal Cancer Onset and Progression